Form 4: Eledon Pharmaceuticals Executive Granted Stock Options and Restricted Stock Units

Bryan E. Smith, General Counsel and Corporate Secretary of Eledon Pharmaceuticals, was granted stock options and restricted stock units on January 10, 2025.

Summary

• Bryan E. Smith, the General Counsel and Corporate Secretary of Eledon Pharmaceuticals, received stock options for 150,500 shares and 64,500 restricted stock units (RSUs) on January 10, 2025.
• The stock options have an exercise price of $4.04 per share and vest over a period of three years, starting January 10, 2026, with quarterly vesting of 6.25% of the underlying shares.
• The RSUs will vest in two tranches, 50% on January 10, 2027, and the remaining 50% on January 10, 2028.
• Both the stock options and RSUs are subject to accelerated vesting under certain conditions, such as termination of employment or a change of control of the company.
• The reporting person must remain in continuous service on each vesting date for the options and RSUs to vest.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of any negative issues.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.
• The accelerated vesting provisions provide some protection for the executive in the event of a change of control or termination.

Risks

• The value of the stock options and RSUs is dependent on the future performance of the company's stock price.
• The vesting of the options and RSUs is contingent on the executive's continued employment with the company.

Future Outlook

The vesting of the stock options and RSUs is contingent on the executive's continued service with the company, suggesting a focus on long-term performance and retention.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract and retain key talent, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• The vesting schedule of the stock options and RSUs is fairly standard for executive compensation packages in the biotech industry.
• Many companies use a combination of stock options and restricted stock units to incentivize executives.
• The vesting periods of three years for options and two to three years for RSUs are typical in the industry.
• Companies like Amgen, Gilead, and Regeneron also use similar equity compensation structures for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, restricted stock units, equity compensation, vesting, Eledon Pharmaceuticals, executive compensation, insider trading